Research programme: tetravalent dengue vaccine - Kaketsuken

Drug Profile

Research programme: tetravalent dengue vaccine - Kaketsuken

Latest Information Update: 20 Sep 2014

Price : $50

At a glance

  • Originator Kaketsuken
  • Developer Kaketsuken; Mahidol University
  • Class Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Dengue

Most Recent Events

  • 16 Sep 2014 Early research in Dengue in Japan (unspecified route)
  • 16 Sep 2014 Kaketsuken receives a grant from Global Health Innovative Technology Fund for vaccine development in Dengue
  • 01 Oct 2011 Kaketsuken and Mahidol university sign material and technology transfer agreement for attenuated dengue strains and related technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top